Brichard; Vincent

Patent Applications and Registrations

Patent applications and USPTO patent grants for Brichard; Vincent.The latest application filed is for "method".

Company Profile

0.9.7

Brichard; Vincent - Rixensart BE
Brichard; Vincent - Brussels BE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Fusion protein Grant 8,309,096 - Blais , et al. November 13, 2	2012-11-13
Method App 20110070268 - Brichard; Vincent ; et al.	2011-03-24
Fusion Protein App 20100029912 - Blais; Normand ; et al.	2010-02-04
Method For Identifying Whether A Patient Will Be Responder or Not to Immunotherapy App 20100021424 - Brichard; Vincent ; et al.	2010-01-28
Use of MAGE A3-Protein D Fusion Antigen in Immunotherapy Combined with Surgery, Chemotherapy or Radiotherapy for the Treatment of Cancer App 20100008980 - Brichard; Vincent ; et al.	2010-01-14
Method Of Treating Mage Positive Cancer App 20090186049 - Brichard; Vincent ; et al.	2009-07-23
Mage-3 and NY-ESO-1 Based Polyvalent Vaccine for Cancer Immunotherapy App 20070243196 - Bruck; Claudine Elvire Marie ; et al.	2007-10-18
Method For Identifying Individuals Suffering From A Cellular Abnormality Some Of Whose Abnormal Cells Present Complexes Of Human Leukocyte Antigen Tyrosinase Derived Peptides, And Methods For Treating Said Individuals Grant 6,669,946 - Boon-Falleur , et al. December 30, 2	2003-12-30
Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of human leukocyte antigen tyrosinase derived peptides, and methods for treating said individuals App 20020128200 - Boon-Falleur, Thierry ; et al.	2002-09-12
Methods for treating subjects with disorders characterized by expression of tumor rejection antigen precursors Grant 6,201,111 - Brichard , et al. March 13, 2	2001-03-13
Precursor processed to at least one tumor rejection antigen presented by HLA-A2 Grant 6,001,975 - Brichard , et al. December 14, 1	1999-12-14
Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2 Grant 5,856,091 - Brichard , et al. January 5, 1	1999-01-05
Tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2 Grant 5,854,203 - Brichard , et al. December 29, 1	1998-12-29
Methods for determining disorders by assaying for a non-tyrosinase, tumor rejection antigen precursor Grant 5,837,476 - Brichard , et al. November 17, 1	1998-11-17
Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2 Grant 5,620,886 - Brichard , et al. April 15, 1	1997-04-15
Isolated, tyrosinase derived peptides and uses thereof Grant 5,530,096 - Wolfel , et al. June 25, 1	1996-06-25

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.